JAGX

Jaguar Health Inc

Stock NASDAQ – Stock Market Prices, News & Analysis

Jaguar Health Inc is a pharmaceutical company that develops natural medicines for the treatment of gastrointestinal disorders in humans and animals.

$ 7.04
15.66 %

Jaguar Health Inc

$ 7.04
15.66 %
JAGX

Jaguar Health Inc is a pharmaceutical company that develops natural medicines for the treatment of gastrointestinal disorders in humans and animals.

Price history of Jaguar Health Inc
Price history of Jaguar Health Inc

Performance & Momentum

6 Months 89.84 %
1 Year 98.36 %
3 Years 99.97 %
5 Years 100.00 %

Strategic Analysis

Jaguar Health Inc • 2026

Jaguar Health Inc positions itself as a specialized player in the development of natural treatments targeting gastrointestinal disorders, employing an innovative biopharmaceutical approach for both human and veterinary markets. Its proposition is based on alternative solutions to conventional drugs, leveraging natural compounds to meet specific clinical needs.

Strengths
  • Targeted niche in gastrointestinal pathologies, offering differentiation through the use of natural compounds.
  • Presence in both human and animal segments, potentially diversifying its market opportunities.
Weaknesses
  • Extremely degraded historical performance over the long term, reflecting major operational and commercial challenges.
  • Lack of recent catalysts and positive news flow, limiting short-term interest for investors.
Momentum

The momentum is flat, with no signs of recovery or visible improvement in the short to medium term. This situation necessitates a cautious approach, with close monitoring of any innovation or unifying development to reverse the trend.

Similar stocks to Jaguar Health Inc

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone